Evidence map›Paper›PMID 29801061›Full record

Trial reportJAMA dermatology2018

Interest and Uptake of MC1R Testing for Melanoma Risk in a Diverse Primary Care Population: A Randomized Clinical Trial.

Jennifer L Hay, Kate Zielaskowski, Kirsten Meyer White, Kimberly Kaphingst, Erika Robers, Dolores Guest, Andrew Sussman, Yvonne Talamantes, Matthew Schwartz, Vivian M Rodríguez and 6 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03130569 (Personalized Genomic Testing for Skin Cancer - Maximizing Utility and Reach), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03130569 nacompletednot on this map

Personalized Genomic Testing for Skin Cancer - Maximizing Utility and Reach

TypeinterventionalSponsorUniversity of New MexicoRan2015 to 2017Enrolled600ConditionsMelanoma (Skin)ArmsWeb-based Module Group
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Effect of Superstitious Beliefs and Risk Intuitions on Genetic Test Decisions.Medical decision making : an international journal of the Society for Medical Decision Making · 2022
    Article
  11. Article
  12. Article
  13. Interest and Utility ofJournal of skin cancer · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Jennifer L HayDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
Kate ZielaskowskiClinical Research Finance, Memorial Sloan Kettering Cancer Center, New York, New York.
Kirsten Meyer WhiteDivision of Epidemiology, Department of Internal Medicine, University of New Mexico, Albuquerque.
Kimberly KaphingstDepartment of Communication, University of Utah, Salt Lake City.
Erika RobersNew Mexico Translation and Transcription, Albuquerque.
Dolores GuestCRTC Population Sciences Academic Unit, University of New Mexico, Albuquerque.
Andrew SussmanDepartment of Family and Community Medicine, University of New Mexico, Albuquerque.
Yvonne TalamantesCRTC Population Sciences Academic Unit, University of New Mexico, Albuquerque.
Matthew SchwartzCRTC Population Sciences Academic Unit, University of New Mexico, Albuquerque.
Vivian M RodríguezCenter for Mind and Body Health, PLLC, Charlottesville, Virginia.
Yuelin LiDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
Elizabeth SchofieldDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
Jessica BigneyDepartment of General Internal Medicine, University of New Mexico, Albuquerque.
Keith HunleyDepartment of Anthropology, University of New Mexico, Albuquerque.
David BullerKlein Buendel Inc, Golden, Colorado.
Marianne BerwickDepartment of Internal Medicine, University of New Mexico, Albuquerque.
University of New Mexico · USMemorial Sloan Kettering Cancer Center · USHuntsman Cancer Institute · USKlein Buendel (United States) · USThe Center for Mind-Body Medicine · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Psychosocial Palliative & Community Research in CancerT32CA009461 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JENNIFER L HAY, Jamie S. Ostroff · 1985 to 2026
$10.1M
Personalized Genomic Testing for Melanoma: Maximizing Personal Utility and ReachR01CA181241 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BERWICK, MARIANNE, HAY, JENNIFER L · 2014 to 2016
$2.1M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA181241NCI NIH HHS T32 CA009461
6 · The paper itself

Abstract

Importance: Germline variants in the MC1R gene are common and confer moderate melanoma risk in those with varied skin types. Approaches to precision skin cancer prevention that include genetic information may promote risk awareness and risk reduction in the general population, including Hispanics. Objective: To examine prevalence of interest in and uptake of MC1R testing in the general population and examine patterns across demographic and skin cancer risk factors. Design, Setting, and Participants: A randomized clinical trial examined interest in and uptake of MC1R testing among patients at University of New Mexico General Internal Medicine clinics. Study participants were randomized to either a usual-care condition (National Cancer Institute skin cancer pamphlet for diverse skin types) or an MC1R test offer. Participants were registered clinic patients (≥6 months) and English or Spanish fluent. Of the 600 participants recruited to the overall trial, the present study included those 499 participants randomized to the MC1R test offer. Interventions: Participants were presented with the option to log onto the study website to read 3 educational modules presenting the rationale, benefits, and drawbacks of MC1R testing. Main Outcomes and Measures: Main outcomes include website log on (yes vs no), saliva test kit request (yes vs no), and saliva test kit return for MC1R testing (yes vs no). Demographic and skin cancer risk factors were examined as potential predictors of test interest and uptake. Results: Of the 499 participants (220 [44%] non-Hispanic white, 242 [48%] Hispanic, 396 [79%] female; mean [SD] age, 54 [14.3] years), 232 (46%) elected to learn about MC1R testing by logging onto the website; 204 (88%) of those who logged on decided to request testing; and 167 (82%) of those who requested testing returned the kit. The strongest predictors of website log on were race/ethnicity and education (non-Hispanic whites were more likely to log on [odds ratio for Hispanics vs non-Hispanic whites, 0.5; 95% CI, 0.3-0.7], as were more highly educated individuals [odds ratio for more than high school vs high school or less, 2.7; 95% CI, 1.7-4.3]). The strongest predictor of ordering the test was sunburn history (odds ratio, 5.4; 95% CI, 2.3-12.9 vs no sunburn history). Conclusions and Relevance: There were moderately high levels of MC1R test interest and uptake in this diverse sample. Addressing potential barriers to testing may be warranted as genomic information becomes integrated into general population approaches to the precision prevention of skin cancer. Trial Registration: ClinicalTrials.gov identifier: NCT03130569.

Indexed as

Health Knowledge, Attitudes, PracticeAdultAgedEducational StatusFemaleGenetic TestingHispanic or LatinoHumansInternetMaleMelanomaMiddle AgedNew MexicoPatient Acceptance of Health CarePatient Education as TopicReceptor, Melanocortin, Type 1MC1R protein, humanReceptor, Melanocortin, Type 1

Identifiers

PMID29801061
PMCPMC5999534
OpenAlexW2800000961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.